William D. Waddill, Director at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 14,990 shares at $21.90 ($329K) on 2024-12-16, disclosed to the SEC on 2024-12-18.
Scheduled sale ($329k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.90 | 3,748 | $82K | 24.9% |
| 2 | $21.90 | 3,748 | $82K | 24.9% |
| 3 | $22.04 | 3,747 | $83K | 25.1% |
| 4 | $22.04 | 3,747 | $83K | 25.1% |
| Total | $21.97 avg | 14,990 | $329K | 100% |
| Filing → |
| PTGX | SELL | 2026-06-01 | $897K | — | Filing → |
| PTGX | SELL | 2026-02-06 | $1.7M | — | Filing → |
| ARWR | SELL | 2025-12-23 | $1.1M | — | Filing → |